RECRUITINGOBSERVATIONAL
Using a Blood Test to Monitor Metastatic Breast Cancer Treatment
Using a Liquid Biopsy to Monitor Metastatic Breast Cancer Treatment
About This Trial
The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.
Who May Be Eligible (Plain English)
Inclusion Criteria
-Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria
-Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]
Locations (2)
Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario
Kingston, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada